RAPS has announced the establishment of a new chapter in Taiwan, its first in Asia.
The Regulatory Affairs Professionals Society (RAPS) has announced the establishment of a new chapter in Taiwan, its first in Asia. The RAPS Taiwan Chapter originated as an affiliate. In making the move to become an official chapter, it will be able to offer additional resources and opportunities to the regulatory community in Taiwan.
“Regulatory professionals from Taiwan can look forward to local training and networking activities while continuing to access RAPS resources for their professional development and career progression,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE.
The chapter is the latest in a series of steps expanding RAPS’ presence in Asia. Last year, RAPS opened two new offices in Asia—a Pan-Asia office in Singapore, serving the entire Asia-Pacific region, and another in Shanghai, serving the regulatory community in China—and also began working with the government of Singapore to develop and implement a new medical device regulatory affairs training program there.
Taiwan Chapter membership is open to all who reside in Taiwan and are involved in regulatory affairs, quality or other functions related to healthcare product regulation. The chapter has a web page in Mandarin Chinese as well as a Facebook page. For information about how to join and membership benefits, contact the RAPS Taiwan Chapter via the web page at http://www.raps-in-taiwan.org.tw.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.